Medical articles
First Phase 3 success for a personalized mRNA therapeutic melanoma vaccine
Merck and Moderna announce that their individualized neoantigenic vaccine, combined with Keytruda, significantly delays the recurrence of operated melanoma. This is a first for this approach.